drugset / Trial / NCT06979674
Study of ESG406 in Adults With Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This study is an open-label, dose-escalation and cohort expansion Phase I study, aiming to evaluate the safety, tolerability, PK characteristics and preliminary efficacy of ESG406, and determine the MTD, RP2D and administration regimens of ESG406. The study includes the dose escalation study in Phase Ia and the cohort expansion study in Phase Ib.
Timeline
- Start
- 2025-06-04
- Primary completion
- 2028-04
- Completion
- 2028-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ESG406 | Unknown | — | Intravenous |
Indications
No indication recorded.